HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 04-28-2005, 05:52 AM   #1
eric
Guest
 
Posts: n/a
Ariad begins cancer study of AP23573

Ariad Pharmaceuticals has initiated patient enrollment for clinical trials of its novel mTOR inhibitor, AP23573. Advanced cancer patients will receive AP23573 as an adjunct to the widely used chemotherapeutic agents, paclitaxel or capecitabine.

These non-randomized, dose-escalation studies will evaluate the safety and tolerability, pharmacokinetics, and anticancer activity of AP23573 in combination with paclitaxel or capecitabine.

The primary goal of these studies is to determine the optimal dosing regimen for AP23573 when used in combination with each of these cytotoxic drugs, predominantly in patients with progressive breast, ovarian, non-small-cell lung, and prostate cancers, as well as certain sarcomas. Up to approximately 110 cancer patients will be enrolled in the two trials at three to five centers in Italy and Switzerland.

Despite advances in cancer therapy, prolonged cancer remission remains difficult to achieve in many types of solid tumors. Additional treatment options are needed for patients whose cancer is progressing and unresponsive to currently available therapies. Combining novel molecularly targeted agents, such as AP23573 with traditional cytotoxic agents may prove to be a more effective treatment for patients with advanced cancers.

The initiation of the new studies sees the beginning of the European phase of the company's global development plan for AP23573, according to chairman and CEO of Ariad, Harvey Berger.

The drug, which has already been fast-tracked by the FDA for the treatment of soft-tissue and bone sarcomas, works by starving cancer cells and shrinks tumors by inhibiting the critical cell-signaling protein, mTOR, which regulates the response of tumor cells to nutrients and growth factors, and controls tumor blood supply and angiogenesis through effects on Vascular Endothelial Growth Factor (VEGF) in tumor and endothelial cells.

Source: Datamonitor
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:31 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter